Literature DB >> 17965846

[Differential therapy of prostate cancer].

T Jäger1, H Rübben, C Börgermann.   

Abstract

Prostate cancer has become the most common malignancy in males worldwide. Standard therapy in local confined prostate cancer with curative intent is a radical ablation of the gland. Brachytherapy seems to be an alternative treatment but long-term results are not yet available. In cases of advanced disease androgen deprivation is applied to eliminate testosterone which is the natural stimulator of tumor growth. The application of chemotherapy is limited to androgen-independent disease without curative intention. Standard chemotherapy is Docetaxel. Both early detection and aftercare are based on measurement of prostate-specific antigen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965846     DOI: 10.1007/s00108-007-1958-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Authors:  Andreas P Berger; Martina Deibl; Hannes Steiner; Jasmin Bektic; Alexandre Pelzer; Robert Spranger; Helmut Klocker; Georg Bartsch; Wolfgang Horninger
Journal:  Prostate       Date:  2005-08-01       Impact factor: 4.104

2.  A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.

Authors:  A A Martinez; J A Gonzalez; A K Chung; L L Kestin; M Balasubramaniam; A C Diokno; E L Ziaja; D S Brabbins; F A Vicini
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Digital rectal examination is barrier to population-based prostate cancer screening.

Authors:  Harris M Nagler; Eric W Gerber; Peter Homel; Joseph R Wagner; Jennifer Norton; Steven Lebovitch; John L Phillips
Journal:  Urology       Date:  2005-06       Impact factor: 2.649

4.  [Early detection of prostatic carcinoma in urologic practice with digital rectal examination and prostate-specific antigen. Early Detection Project Group].

Authors:  H J Luboldt; J Hüsing; J E Altwein; K H Bichler; D Czaja; P Fornara; K H Jöckel; K Schalkhäuser; L Weissbach; M Wirth; H Rübben
Journal:  Urologe A       Date:  2000-07       Impact factor: 0.639

Review 5.  Surgical treatment of localized prostate cancer.

Authors:  Jan-Erik Damber; Ali Khatami
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

6.  Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions.

Authors:  Tillmann Loch; Ursula Eppelmann; Jan Lehmann; Bernd Wullich; Annemie Loch; Michael Stöckle
Journal:  World J Urol       Date:  2004-12-01       Impact factor: 4.226

7.  Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy.

Authors:  Jim C Hu; Rebecca A Nelson; Timothy G Wilson; Mark H Kawachi; S Adam Ramin; Clayton Lau; Laura E Crocitto
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.

Authors:  W J Ellis; M P Chetner; S D Preston; M K Brawer
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

10.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

Authors:  P H Gann; C H Hennekens; M J Stampfer
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.